Jaguar Health (JAGX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
6 May, 2026Executive summary
Supplement corrects the Annual Meeting date to Friday, May 22, 2026, amending a previous error that listed it as Tuesday, August 19, 2025.
All other information in the Proxy Statement remains unchanged and should be read in conjunction with this supplement.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Jaguar Health
- Major stock issuances to C/M Capital and board governance changes are up for shareholder vote.JAGX
Proxy filing30 Apr 2026 - Shareholders will vote on major stock issuances to C/M Capital, director election, and auditor ratification.JAGXProxy filing21 Apr 2026
- Q4 2025 revenue up 5% sequentially; $16M upfront from out-license deal, net loss at $53.6M.JAGXQ4 202510 Apr 2026
- Proxy seeks approval for major share increase, reverse splits, and note-related share issuance.JAGXProxy filing24 Mar 2026
- Proxy seeks approval for share increase, reverse splits, and debt-related share issuance.JAGXProxy Filing13 Mar 2026
- Non-dilutive funding accelerates rare disease pipeline with strong clinical and regulatory momentum.JAGXLife Sciences Virtual Investor Forum12 Mar 2026
- Clinically meaningful benefit seen in breast and respiratory cancer subgroups despite missing the main endpoint.JAGXStudy Result3 Feb 2026
- Q2 revenue up 16% sequentially; Gelclair launch and crofelemer trials drive outlook.JAGXQ2 20242 Feb 2026
- Strong clinical pipeline, revenue growth, and new launches position for near-term catalysts.JAGXH.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026